Top

Published in:

01-09-2015 | Review Article

Myeloid proliferations associated with Down syndrome

Author: Alan B. Cantor

Published in: Journal of Hematopathology | Issue 3/2015

Abstract

A subset of Down syndrome (DS) (trisomy 21) neonates is born with a unique erythromegakaryocytic myeloproliferative disorder that spontaneously resolves over the first few months of life (DS-transient abnormal myelopoiesis (DS-TAM); previously called DS-transient myeloproliferative disorder (DS-TMD) and DS-transient leukemia (DS-TL)). These infants are at high risk for developing subsequent acute megakaryoblastic leukemia (myeloid leukemia associated with Down syndrome (ML-DS); previously called DS-acute megakaryoblastic leukemia (DS-AMKL)). The molecular basis for DS-TAM/ML-DS remained mysterious for a long period of time. However, new genetic insights have been gained over the past 12 years that have begun to decipher the pathophysiology of this unusual disorder.

Roberts I, Alford K, Hall G, Juban G, Richmond H, Norton A, Vallance G, Perkins K, Marchi E, McGowan S, Roy A, Cowan G, Anthony M, Gupta A et al (2013) GATA1-mutant clones are frequent and often unsuspected in babies with Down syndrome: identification of a population at risk of leukemia. Blood 122:3908–3917PubMedCentralPubMedCrossRef

Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellstrom-Lindberg E, Tefferi A, Bloomfield CD (2009) The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114:937–951PubMedCrossRef

Zipursky A (2003) Transient leukaemia—a benign form of leukaemia in newborn infants with trisomy 21. Br J Haematol 120:930–938PubMedCrossRef

Lange B (2000) The management of neoplastic disorders of haematopoiesis in children with Down’s syndrome. Br J Haematol 110:512–524PubMedCrossRef

Pine SR, Guo Q, Yin C, Jayabose S, Druschel CM, Sandoval C (2007) Incidence and clinical implications of GATA1 mutations in newborns with Down syndrome. Blood 110:2128–2131PubMedCrossRef

Massey GV, Zipursky A, Chang MN, Doyle JJ, Nasim S, Taub JW, Ravindranath Y, Dahl G, Weinstein HJ (2006) A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children’s Oncology Group (COG) study POG-9481. Blood 107:4606–4613PubMedCrossRef

Klusmann JH, Creutzig U, Zimmermann M, Dworzak M, Jorch N, Langebrake C, Pekrun A, Macakova-Reinhardt K, Reinhardt D (2008) Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood 111:2991–2998PubMedCentralPubMedCrossRef

Muramatsu H, Kato K, Watanabe N, Matsumoto K, Nakamura T, Horikoshi Y, Mimaya J, Suzuki C, Hayakawa M, Kojima S (2008) Risk factors for early death in neonates with Down syndrome and transient leukaemia. Br J Haematol 142:610–615PubMedCrossRef

Gamis AS, Alonzo TA, Gerbing RB, Hilden JM, Sorrell AD, Sharma M, Loew TW, Arceci RJ, Barnard D, Doyle J, Massey G, Perentesis J, Ravindranath Y, Taub J et al (2011) Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children’s Oncology Group Study A2971. Blood 118:6752–6759, quiz 6996PubMedCentralPubMedCrossRef

10.

Zipursky A, Poon A, Doyle J (1992) Leukemia in Down syndrome: a review. Pediatr Hematol Oncol 9:139–149PubMedCrossRef

11.

Langebrake C, Creutzig U, Reinhardt D (2005) Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts. Klin Padiatr 217:126–134PubMedCrossRef

12.

Bourquin JP, Subramanian A, Langebrake C, Reinhardt D, Bernard O, Ballerini P, Baruchel A, Cave H, Dastugue N, Hasle H, Kaspers GL, Lessard M, Michaux L, Vyas P et al (2006) Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling. Proc Natl Acad Sci U S A 103:3339–3344PubMedCentralPubMedCrossRef

13.

Wechsler J, Greene M, McDevitt MA, Anastasi J, Karp JE, Le Beau MM, Crispino JD (2002) Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet 32:148–152PubMedCrossRef

14.

Mundschau G, Gurbuxani S, Gamis AS, Greene ME, Arceci RJ, Crispino JD (2003) Mutagenesis of GATA1 is an initiating event in Down syndrome leukemogenesis. Blood 101:4298–4300PubMedCrossRef

15.

Greene ME, Mundschau G, Wechsler J, McDevitt M, Gamis A, Karp J, Gurbuxani S, Arceci R, Crispino JD (2003) Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome. Blood Cells Mol Dis 31:351–356PubMedCrossRef

16.

Rainis L, Bercovich D, Strehl S, Teigler-Schlegel A, Stark B, Trka J, Amariglio N, Biondi A, Muler I, Rechavi G, Kempski H, Haas OA, Izraeli S (2003) Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21. Blood 102:981–986PubMedCrossRef

17.

Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A (2003) GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood 101:4301–4304PubMedCrossRef

18.

Xu G, Nagano M, Kanezaki R, Toki T, Hayashi Y, Taketani T, Taki T, Mitui T, Koike K, Kato K, Imaizumi M, Sekine I, Ikeda Y, Hanada R et al (2003) Frequent mutations in the GATA-1 gene in the transient myeloproliferative disorder of Down syndrome. Blood 102:2960–2968PubMedCrossRef

19.

Alford KA, Reinhardt K, Garnett C, Norton A, Bohmer K, von Neuhoff C, Kolenova A, Marchi E, Klusmann JH, Roberts I, Hasle H, Reinhardt D, Vyas P (2011) Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. Blood 118:2222–2238PubMedCrossRef

20.

Calligaris R, Bottardi S, Cogoi S, Apezteguia I, Santoro C (1995) Alternative translation initiation site usage results in two functionally distinct forms of the GATA-1 transcription factor. Proc Natl Acad Sci U S A 92:11598–11602PubMedCentralPubMedCrossRef

21.

Ludwig LS, Gazda HT, Eng JC, Eichhorn SW, Thiru P, Ghazvinian R, George TI, Gotlib JR, Beggs AH, Sieff CA, Lodish HF, Lander ES, Sankaran VG (2014) Altered translation of GATA1 in Diamond-Blackfan anemia. Nat Med 20:748–753PubMedCentralPubMedCrossRef

22.

Fujiwara Y, Browne CP, Cunniff K, Goff SC, Orkin SH (1996) Arrested development of embryonic red cell precursors in mouse embryos lacking transcription factor GATA-1. Proc Natl Acad Sci U S A 93:12355–12358PubMedCentralPubMedCrossRef

23.

Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH (1997) A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. Embo J 16:3965–3973PubMedCentralPubMedCrossRef

24.

Yu C, Cantor AB, Yang H, Browne C, Wells RA, Fujiwara Y, Orkin SH (2002) Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med 195:1387–1395PubMedCentralPubMedCrossRef

25.

Zon LI, Gurish MF, Stevens RL, Mather C, Reynolds DS, Austen KF, Orkin SH (1991) GATA-binding transcription factors in mast cells regulate the promoter of the mast cell carboxypeptidase A gene. J Biol Chem 266:22948–22953PubMed

26.

Migliaccio AR, Rana RA, Sanchez M, Lorenzini R, Centurione L, Bianchi L, Vannucchi AM, Migliaccio G, Orkin SH (2003) GATA-1 as a regulator of mast cell differentiation revealed by the phenotype of the GATA-1low mouse mutant. J Exp Med 197:281–296PubMedCentralPubMedCrossRef

27.

Vyas P, Ault K, Jackson CW, Orkin SH, Shivdasani RA (1999) Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood 93:2867–2875PubMed

28.

Vannucchi AM, Bianchi L, Cellai C, Paoletti F, Rana RA, Lorenzini R, Migliaccio G, Migliaccio AR (2002) Development of myelofibrosis in mice genetically impaired for GATA-1 expression (GATA-1(low) mice). Blood 100:1123–1132PubMedCrossRef

29.

Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH (2005) Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet 37:613–619PubMedCrossRef

30.

Klusmann JH, Godinho FJ, Heitmann K, Maroz A, Koch ML, Reinhardt D, Orkin SH, Li Z (2010) Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes Dev 24:1659–1672PubMedCentralPubMedCrossRef

31.

Woo AJ, Wieland K, Huang H, Akie TE, Piers T, Kim J, Cantor AB (2013) Developmental differences in IFN signaling affect GATA1s-induced megakaryocyte hyperproliferation. J Clin Inv 123:3292–3304CrossRef

32.

Ahmed M, Sternberg A, Hall G, Thomas A, Smith O, O’Marcaigh A, Wynn R, Stevens R, Addison M, King D, Stewart B, Gibson B, Roberts I, Vyas P (2004) Natural history of GATA1 mutations in Down syndrome. Blood 103:2480–2489PubMedCrossRef

33.

Yoshida K, Toki T, Okuno Y, Kanezaki R, Shiraishi Y, Sato-Otsubo A, Sanada M, Park MJ, Terui K, Suzuki H, Kon A, Nagata Y, Sato Y, Wang R et al (2013) The landscape of somatic mutations in Down syndrome-related myeloid disorders. Nat Genet 45:1293–1299PubMedCrossRef

34.

Taub JW, Mundschau G, Ge Y, Poulik JM, Qureshi F, Jensen T, James SJ, Matherly LH, Wechsler J, Crispino JD (2004) Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood 104:1588–1589PubMedCrossRef

35.

Hollanda LM, Lima CS, Cunha AF, Albuquerque DM, Vassallo J, Ozelo MC, Joazeiro PP, Saad ST, Costa FF (2006) An inherited mutation leading to production of only the short isoform of GATA-1 is associated with impaired erythropoiesis. Nat Genet 38:807–812PubMedCrossRef

36.

Chou ST, Opalinska JB, Yao Y, Fernandes MA, Kalota A, Brooks JS, Choi JK, Gewirtz AM, Danet-Desnoyers GA, Nemiroff RL, Weiss MJ (2008) Trisomy 21 enhances human fetal erythro-megakaryocytic development. Blood 112:4503–4506PubMedCentralPubMedCrossRef

37.

Roy A, Cowan G, Mead AJ, Filippi S, Bohn G, Chaidos A, Tunstall O, Chan JK, Choolani M, Bennett P, Kumar S, Atkinson D, Wyatt-Ashmead J, Hu M et al (2012) Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21. Proc Natl Acad Sci U S A 109:17579–17584PubMedCentralPubMedCrossRef

38.

Tunstall-Pedoe O, Roy A, Karadimitris A, de la Fuente J, Fisk NM, Bennett P, Norton A, Vyas P, Roberts I (2008) Abnormalities in the myeloid progenitor compartment in Down syndrome fetal liver precede acquisition of GATA1 mutations. Blood 112:4507–4511PubMedCrossRef

39.

Roberts I, O’Connor D, Roy A, Cowan G, Vyas P (2013) The impact of trisomy 21 on foetal haematopoiesis. Blood Cells Mol Dis 51:277–281PubMedCrossRef

40.

Maclean GA, Menne TF, Guo G, Sanchez DJ, Park IH, Daley GQ, Orkin SH (2012) Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. Proc Natl Acad Sci U S A 109:17567–17572PubMedCentralPubMedCrossRef

41.

Kirsammer G, Jilani S, Liu H, Davis E, Gurbuxani S, Le Beau MM, Crispino JD (2008) Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome. Blood 111:767–775PubMedCentralPubMedCrossRef

42.

Stankiewicz MJ, Crispino JD (2013) AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL. Leukemia 27:1339–1347PubMedCentralPubMedCrossRef

43.

Ng AP, Hyland CD, Metcalf D, Carmichael CL, Loughran SJ, Di Rago L, Kile BT, Alexander WS (2010) Trisomy of Erg is required for myeloproliferation in a mouse model of Down syndrome. Blood 115:3966–3969PubMedCrossRef

44.

Ge Y, LaFiura KM, Dombkowski AA, Chen Q, Payton SG, Buck SA, Salagrama S, Diakiw AE, Matherly LH, Taub JW (2008) The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy. Leukemia 22:521–529PubMedCrossRef

45.

Klusmann JH, Li Z, Bohmer K, Maroz A, Koch ML, Emmrich S, Godinho FJ, Orkin SH, Reinhardt D (2010) miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia. Genes Dev 24:478–490PubMedCentralPubMedCrossRef

46.

Blink M, van den Heuvel-Eibrink MM, Aalbers AM, Balgobind BV, Hollink IH, Meijerink JP, van der Velden VH, Beverloo BH, de Haas V, Hasle H, Reinhardt D, Klusmann JH, Pieters R, Calado RT et al (2012) High frequency of copy number alterations in myeloid leukaemia of Down syndrome. Br J Haematol 158:800–803PubMedCrossRef

47.

Blink M, Zimmermann M, von Neuhoff C, Reinhardt D, de Haas V, Hasle H, O’Brien MM, Stark B, Tandonnet J, Pession A, Tousovska K, Cheuk DK, Kudo K, Taga T et al (2014) Normal karyotype is a poor prognostic factor in myeloid leukemia of Down syndrome: a retrospective, international study. Haematologica 99:299–307PubMedCentralPubMedCrossRef

48.

Blink M, Buitenkamp TD, van den Heuvel-Eibrink MM, Danen-van Oorschot AA, de Haas V, Reinhardt D, Klusmann JH, Zimmermann M, Devidas M, Carroll AJ, Basso G, Pession A, Hasle H, Pieters R et al (2011) Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. Leukemia 25:1365–1368PubMedCrossRef

49.

Walters DK, Mercher T, Gu TL, O’Hare T, Tyner JW, Loriaux M, Goss VL, Lee KA, Eide CA, Wong MJ, Stoffregen EP, McGreevey L, Nardone J, Moore SA et al (2006) Activating alleles of JAK3 in acute megakaryoblastic leukemia. Cancer Cell 10:65–75PubMedCrossRef

50.

Malinge S, Ragu C, Della-Valle V, Pisani D, Constantinescu SN, Perez C, Villeval JL, Reinhardt D, Landman-Parker J, Michaux L, Dastugue N, Baruchel A, Vainchenker W, Bourquin JP et al (2008) Activating mutations in human acute megakaryoblastic leukemia. Blood 112:4220–4226PubMedCrossRef

51.

Malkin D, Brown EJ, Zipursky A (2000) The role of p53 in megakaryocyte differentiation and the megakaryocytic leukemias of Down syndrome. Cancer Genet Cytogenet 116:1–5PubMedCrossRef

52.

Homans AC, Verissimo AM, Vlacha V (1993) Transient abnormal myelopoiesis of infancy associated with trisomy 21. Amn J Pediatr Hematol Oncol 15:392–399

53.

Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M (2005) AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia 19:1355–1360PubMedCrossRef

54.

Rao A, Hills RK, Stiller C, Gibson BE, de Graaf SS, Hann IM, O’Marcaigh A, Wheatley K, Webb DK (2006) Treatment for myeloid leukaemia of Down syndrome: population-based experience in the UK and results from the Medical Research Council AML 10 and AML 12 trials. Br J Haematol 132:576–583PubMedCrossRef

55.

Gamis AS, Woods WG, Alonzo TA, Buxton A, Lange B, Barnard DR, Gold S, Smith FO (2003) Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: a report from the Children’s Cancer Group Study 2891. J Clin Oncol : Off J Am Soc Clin Oncol 21:3415–3422CrossRef

56.

Ge Y, Stout ML, Tatman DA, Jensen TL, Buck S, Thomas RL, Ravindranath Y, Matherly LH, Taub JW (2005) GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. J Natl Cancer Inst 97:226–231PubMedCrossRef

57.

Malinge S, Izraeli S, Crispino JD (2009) Insights into the manifestations, outcomes, and mechanisms of leukemogenesis in Down syndrome. Blood 113:2619–2628PubMedCentralPubMedCrossRef

58.

Gurbuxani S, Vyas P, Crispino JD (2004) Recent insights into the mechanisms of myeloid leukemogenesis in Down syndrome. Blood 103:399–406PubMedCrossRef

59.

Gamis AS, Smith FO (2012) Transient myeloproliferative disorder in children with Down syndrome: clarity to this enigmatic disorder. Br J Haematol 159:277–287PubMedCrossRef

60.

Hitzler JK, Zipursky A (2005) Origins of leukaemia in children with Down syndrome. Nature reviews. Cancer 5:11–20PubMed

61.

Cantor AB (2005) GATA transcription factors in hematologic disease. Int J Hematol 81:378–384PubMedCrossRef

Title: Myeloid proliferations associated with Down syndrome
Author: Alan B. Cantor
Publication date: 01-09-2015
Publisher: Springer Berlin Heidelberg
Published in: Journal of Hematopathology / Issue 3/2015
Print ISSN: 1868-9256
Electronic ISSN: 1865-5785
DOI: https://doi.org/10.1007/s12308-014-0225-0

At a glance: The STEP trials

Springer Medicine

Myeloid proliferations associated with Down syndrome

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

Bone marrow failure syndromes, a practical approach to diagnosis

Pediatric myelodysplastic/myeloproliferative neoplasms and related diseases

Deconstructing the diagnosis of hemophagocytic lymphohistiocytosis using illustrative cases

Molecular characterization and testing in acute myeloid leukemia

Flow cytometry in the diagnosis and monitoring of acute leukemia in children

Paediatric hematopathology: something real special